乾燥症と局所保湿剤の使用
表皮透過性 局所保湿剤塗布後の乾皮症のバリア機能と角質層水和
The primary hypothesis is that routine measurement of trans epidermal water loss (TEWL) rates and stratum corneum (SC) hydration levels will promote patient adherence to maintenance moisturizer therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with xerosis receive moisturizer therapy and are randomized to receive either no intervention, a weekly electronic survey to assess patient's response to daily moisturizer, or daily monitoring of the effectiveness of a moisturizer with a portable hydration measurement device. The study team will measure adherence to daily moisturizer use objectively in all three groups with electronic monitors attached to the containers of the moisturizer. The adherence measure will allow the study determine how well moisturizers work for xerosis when that are well used. The study team anticipate that in the no intervention group, adherence will be abysmal and that in the group reporting their response to treatment weekly, adherence will be much better. This will give the study team negative and positive controls for assessing the effect of home barrier monitoring on treatment adherence.
調査の概要
状態
詳細な説明
Adult subjects will be offered an opportunity to participate in the study. Subjects will have a diagnosis of xerosis in the context (current or historic) of atopic dermatitis. A total of 30 subjects will be enrolled. After consent and basic demographics, a study team member will use the GPSkin Barrier® device to measure the baseline moisture level of the inner wrist, inner elbow, and dorsal hand of all subjects. Subjects will also fill out questionnaires pertaining to quality of life, measures of predictors of adherence, and severity of xerosis.
Subjects will be randomized into one of three arms: the control group (n= 10), the electronic interaction group to assess patient's response to daily moisturizer (n=10), or the GPSkin group (n=10). All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis. The digital interaction group will receive a survey by email each week asking about their Cetaphil use. The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily. Subjects will be instructed to use the Cetaphil once daily. Subjects will return at 3 months. At this visit, the data from the electronic adherence monitoring will be downloaded, the Cetaphil will be weighed, the patient will fill out the same questionnaires (quality of life, measures of predictors of adherence, and severity of xerosis), and the stratum corneum hydration level will be measured. The intervention subjects will be evaluated on their use of the GPSkin Barrier® to measure their stratum corneum hydration
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
North Carolina
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences Department of Dermatology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subject is 18 years of age or older.
- Subject has a working knowledge of English.
- Subject with a diagnosis of xerosis in the context (current or historic) of atopic dermatitis
Exclusion Criteria:
- Subjects under 18 years of age.
- Subject does not have a working knowledge of English.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Control Group
All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis |
All 30 patients to receive |
|
他の:Digital Interaction Group
The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence. |
All 30 patients to receive 10 patients to electronic surveys about moisturizer use |
|
他の:GPSkin group
The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily. |
All 30 patients to receive Measuring moisture in the skin |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Xerosis Severity
時間枠:At Baseline
|
Dry Skin/Ichthyosis Area and Severity Index (DASI) |
At Baseline
|
|
Xerosis Severity
時間枠:Change from Baseline to 3 months
|
Dry Skin/Ichthyosis Area and Severity Index (DASI) |
Change from Baseline to 3 months
|
|
Adherence - Moisturizer
時間枠:3 months
|
MEMs data of daily use of moisturizer |
3 months
|
|
Adherence - Moisturizer
時間枠:Baseline
|
Weight of moisturizer |
Baseline
|
|
Adherence - Moisturizer
時間枠:Change from baseline to 3 months
|
Weight of moisturizer |
Change from baseline to 3 months
|
|
Transepidermal water loss (TEWL) rates
時間枠:Baseline
|
Use of the GPSkin Barrier device a portable hydration measurement device that measures TEWL rates |
Baseline
|
|
Transepidermal water loss (TEWL) rates
時間枠:Change from baseline to 3 month
|
Use of the GPSkin Barrier device a portable hydration measurement device that measures TEWL rates |
Change from baseline to 3 month
|
協力者と研究者
協力者
捜査官
- 主任研究者:Steven R Feldman, MD, PhD、Wake Forest University Health Sciences
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- IRB00062695
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Team will determine what will be shared at later time
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。